Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Painless ALA-PDT vs Isotretinoin for Moderate and Severe Acne Vulgaris
NCT04167982Unknown
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Mar 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 5-aminolevulinic acid in acne vulgaris (3 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: The clearance rate of Moderate or Severe Acne. Status: unknown.
02
Drugs
5-aminolevulinic acid
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04167982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167982.